CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing
Allogeneic CAR-T therapies aim to replace six-figure bespoke cell production with off-the-shelf donor lines.
0 reactions · anonymous
From bespoke to batch
First-gen CAR-T harvests a patient's own cells, engineers them, and infuses them back — a weeks-long, million-dollar logistics feat. Donor-derived lines can be made in batches and given immediately.
Early allogeneic results trail autologous on durability, but graft-versus-tumour effects are narrowing the gap.
Building incoffeed — a daily editorial on tech, AI, fintech and business. Co-founder & editor.
Discussion
0// No comments yet — be the first to start the discussion.
